Performance Enhancing Drugs Market Research Report –Forecast till 2027

Performance Enhancing Drugs Market Research Report: By Types (Ergogenic Aids, Nootropic), By Products (Pills, Injections, Patches), By End Users (Athletes, Body Builders, Students, Militaries), and Others- Forecast Till 2027

ID: MRFR/Pharma/3274-HCR | February 2021 | Region: Global | 90 pages

Performance Enhancing Drugs Market Overview


As the name suggests, performance-enhancing drugs refer to those chemical agents that provide an advantage to the athlete and helps in boosting athletic performance. Enlargement of muscles, and increasing the carrying capacity of blood’s oxygen are some of the effects that are a result of consuming the performance-enhancing drugs before competition for the athletes. As per the Health Research Funding and their conducted research in 2015, as many as, 1,084,000 Americans were known to consume the anabolic performance-enhancing drugs. Also, the other stats include the willingness of people to consume these drugs even after learning the fact that these might shorten their life span. The quantum of these stats stands at 57%. These drugs can be categorized as aids and steroids which help the athletes enjoy the physical edge during the competition. Also, the athlete is likely to have a mental state to give their best post the drug use, as well. The steroids which the athletes use is a modified testosterone version. These have medical uses but cannot be categorized as performance enhancers.


Owing to the growth in acceptance and vibrant use, the performance enhancing drugs market size is likely to grow at a 4.8% CAGR rate by the end of the ongoing forecast period in 2023.


 COVID 19 Analysis of Performance Enhancing Drugs Market


Since the arrival of the pandemic, the demand for performance-enhancing drugs is constant but is not experiencing any growth. The pandemic has accelerated new trends and techniques and people are questioning the quality of their life and their lifestyle. To have a better and qualitative life, people are shifting to healthier alternates and shifting to better eating habits including health supplements. Also, during the pandemic, the lockdown, social distancing, and event cancellations are reducing competition. Hence, the demand for performance-enhancing drugs is stagnant. Also, the associated health risks with the same are pushing people to opt for alternate and healthier means. While others are eliminating the use and go natural.


The key market players that are functional in major regions of the world and hence, are opting for key strategies opportunities that will help them grow by the end of the forecast period in 2023. The players are opting for product developments and enhancements through mergers and acquisitions. This has a major role to play in increasing the will for people to use these drugs and the widescale awareness, reliable information, and demand related to the same.


Performance Enhancing Drugs Market Dynamics


Drivers


There is an increase in the use of anabolic steroids amongst the target audience and patients having medical histories related to different kinds of diseases. Also, these drugs are presenting a reliable use for the treatment of health issues like anemia, and certain types of breast cancer alongside the others that prevail amongst the patients. These factors are playing a major role and acting as drivers to fuel the growth for the performance enhancing drugs market on a global level for the forecast period ending in 2023.


Restraints


Even though there are varied uses of such drugs, the performance enhancing drugs market is exposed to certain restraints on its way of global growth as per the prediction. The side effects due to the use of these drugs real and a matter of concern. In males, acne breakout is a common risk and there are other health issues like reduced sperm production. Females witness issues like masculinization, a higher risk of a heart attack, and others. Also, the government is proposing stricter guidelines that are restricting the performance enhancing drugs market growth during the forecast period that ends in 2023.


is exposed to certain restraints on its way of global growth as per the prediction. The side effects due to the use of these drugs real and a matter of concern. In males, acne breakout is a common risk and there are other health issues like reduced sperm production. Females witness issues like masculinization, a higher risk of a heart attack, and others. Also, the government is proposing stricter guidelines that are restricting the performance enhancing drugs market growth during the forecast period that ends in 2023.


Technology Analysis


Most of the athletes that belong to the developed and developing nations are demanding the use of performance-enhancing drugs on a large scale. There is a rise in the positive tests for anabolic drugs across the world and the figure has touched 50.6% as reported by the Health Research funding. This shows that there is a growth in the acceptance of these drugs and there is a growth in the utilization of the same for performance. The potential audience is witnessing an increase in the per capita income for people which is further pushing them to invest in the consumption of these drugs.


Figure 1:- Global performance enhancing drugs market share, by region Performance Enhancing Drugs Market


Sources: WHO, annual reports, press release, white paper, and company presentation 


Study Objectives



  • To understand the futuristic scope of the performance enhancing drugs market as per the market dynamics like drivers, opportunities, risks, and restraints and further predict the expected CAGR rate of growth and market evaluation

  • To analyze the scope of the market by surveying the performance enhancing drugs market segments functioning across regions worldwide and also understanding their scope during the forecast period ending in 2023

  • To review the market scale of operations by having an idea about the prominent companies and other key players in the mushrooming regions and also learning about the competitive degree in the performance enhancing drugs market owing to the recent developments undertaken by the companies


 


Performance Enhancing Drugs Market Segment Overview


The global performance enhancing drugs market is largely dependent on the functioning of the various market segments that are available across various regions in the globe. The segments prove an understanding of the revenue cycle which further helps in predicting the market valuation. The market has been segmented based on the following:


Type


The type segment of the global performance enhancing drugs market includes ergogenic acids and nootropics amongst others. Further, the ergogenic acids have sub-segments like human growth syndrome, DHEA, anabolic steroids, and others. The nootropic segment includes racetams, acetylcholine intermediates, and ampakines, amongst others.


Product


The product segment of the global performance enhancing drugs market includes pills and patches, alongside injections on the requirement. 


End-users


The market end-users are athletes and bodybuilders, militaries, and students.


Performance Enhancing Drugs Market Regional Analysis


Owing to the historic trends and efforts of the performance enhancing drugs market players present, the North American region is likely to have a dominant hand over the global market operations. The companies help in generating a high per capita income for the population in regions like Canada and the USA. this is increasing the purchasing power of the people. Also, in the historic year of 2017, the American Cancer Society functioning in the USA, reported a huge rise in the cases of women suffering from breast cancer. The number reached 252,710 and the death toll because of the same reached 40, 610. Hence, to cure such diseases and put the patients in a better position, the demand for anabolic steroids is enhancing and this will boost the global performance enhancing drugs market growth during the ongoing forecast period that ends in 2023.


Performance Enhancing Drugs Market Competitive Landscape


The report helps to analyze the competitive degree that prevails in the performance enhancing drugs market and for the same, it is mandatory to understand the prominent players that are putting efforts in these regions. The players are as follows:



  • Taj Pharmaceuticals Limited. (India)

  • Eli Lilly and Company. (the U.S.)

  • Balkan Pharmaceuticals. (Europe)

  • Onnit Labs, LLC. (the U.S.)

  • Douglas Laboratories. (the U.S.)

  • Bayer AG (Europe)

  • BrainAlert, LLC (U.S.)

  • AstraZeneca (Europe)

  • Novo Nordisk A/S (Europe)


 Recent Developments



  • The European performance enhancing drugs market players are ensuring a constant and reliable place for the availability of funds for innovation and research. Also, the results of such drugs are promising as the people are accepting and demanding them on a large basis. This will help the market with the much-needed boost.

  • The APAC companies are targeting performance enhancing drugs market growth through investing in creating awareness related to the drugs in the mushrooming economies. The market has a lot of scope and desirable opportunities that are the main target for these companies by the end of the forecast period in 2023.

  • The African healthcare service providers and startups are open for mergers and acquisitions that will help the market grow and provide the target audience with these drugs. The players are largely interested in developing the healthcare sector by expanding the development expenditure.

  • The US and Canadian companies are on the way to develop a treatment for issues related to the side effects and health concerns raised by the performance-enhancing drugs. This step has been taken to cater to the huge demand for the performance enhancing drugs market .


 Intended Audience



  • Athletes

  • Persons engaged in body-building and competitions

  • Students

  • Wrestlers


 Report Overview


The curated report is a step to understand the performance enhancing drugs market dynamics and further conduct the performance-enhancing drugs market analysis to predict the CAGR rate and market valuation by the end of the forecast period in 2023. The report discusses the impact of the pandemic on the market operations and the steps taken by the government and key market players to bounce back. The report also discusses the market segmentation that has the potential to bring a change in the final market valuation by their functioning in various regions across the globe. Also, to judge the competitive degree, the market report mentions the recent developments undertaken by the performance enhancing drugs market players for final evaluation.


 



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   2018-2023: 4.8%
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Types, Products, and End-Users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Taj Pharmaceuticals Limited. (India), Balkan Pharmaceuticals. (Europe), Bayer AG (Europe), AstraZeneca (Europe), Novo Nordisk A/S (Europe), BrainAlert, LLC (U.S.), Douglas Laboratories. (U.S.), Onnit Labs, LLC. (U.S.), Eli Lilly and Company. (U.S.)
  Key Market Opportunities   Continuously Developing Economies
  Key Market Drivers   Growing acceptance of performance enhancing drugs among amateur bodybuilders and fitness enthusiasts


Frequently Asked Questions (FAQ) :


Performance enhancing drugs are drugs that elevate the consumer’s athletic performance by providing benefits such as muscle enlargement and increased oxygen carrying capacity.

The Performance Enhancing Drugs Market is expected to exhibit a strong 4.8% CAGR over the forecast period from 2018 to 2023.

Growing acceptance of performance enhancing drugs among amateur bodybuilders and fitness enthusiasts is the major driver for the market.

The Americas dominate the Global Performance Enhancing Drugs Market.

Leading players in the Performance Enhancing Drugs Market include Novo Nordisk, Taj Pharmaceuticals, and Bayer AG, among others.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Performance Enhancing Drugs Market, by Type

6.1 Introduction

6.2 Ergogenic Aids

Market Estimates & Forecast, 2020 – 2027

6.2.1 Anabolic Steroids

6.2.2 Dehydroepiandrosterone (DHEA)

6.2.3 Human Growth Hormone

6.2.4 Others

6.3 Nootropic

Market Estimates & Forecast, 2020 – 2027

6.3.1 Racetams

6.3.2 Ampakines

6.3.3 Choline & Acetylcholine Intermediates

6.3.4 Others

6.4 Others

Chapter 7. Global Performance Enhancing Drugs Market, by Products

7.1 Introduction

7.2 Pills

Market Estimates & Forecast, 2020 – 2027

7.3 Injections

Market Estimates & Forecast, 2020 – 2027

7.4 Patches

Market Estimates & Forecast, 2020 – 2027

7.5 Others

Market Estimates & Forecast, 2020 – 2027

Chapter 8 Global Performance Enhancing Drugs Market, by End User

8.1 Introduction

8.2 Athletes

8.2.1 Market Estimates & Forecast, 2020 – 2027

8.3 Body Builders

8.2.2 Market Estimates & Forecast, 2020 – 2027

8.4 Students

8.2.3 Market Estimates & Forecast, 2020 – 2027

8.5 Militaries

8.2.4 Market Estimates & Forecast, 2020 – 2027

8.6 Others

8.2.5 Market Estimates & Forecast, 2020 – 2027

Chapter 9. Global Performance Enhancing Drugs Market, by Region

9.1 Introduction

9.2 America

9.2.1 North America

9.2.1.1 US

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 Italy

9.3.1.4 Spain

9.3.1.5 UK

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

Chapter 10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

Chapter 11 Company Profiles

11.1 Taj Pharmaceuticals Limited.

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Balkan Pharmaceuticals.

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 Bayer AG

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 AstraZeneca

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Novo Nordisk A/S

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.5.5 SWOT Analysis

11.6 BrainAlert, LLC

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.6.5 SWOT Analysis

11.7 Douglas Laboratories.

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Onnit Labs, LLC.

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.8 Eli Lilly and Company.

11.8.1 Overview

11.8.2 Product Overview

11.8.3 Financials

11.8.4 Key Developments

11.8.5 SWOT Analysis

11.9 Others

Chapter 12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Performance Enhancing Drugs Market

Chapter 13 Appendix

LIST OF TABLES

Table 1 Performance Enhancing Drugs Industry Synopsis, 2020 – 2027

Table 2 Global Performance Enhancing Drugs Market Estimates and Forecast, 2020 – 2027, (USD Million)

Table 3 Global Performance Enhancing Drugs Market by Region, 2020 – 2027, (USD Million)

Table 4 Global Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 5 Global Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 6 Global Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

Table 7 North America Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 8 North America Performance Enhancing Drugs by Products, 2020 – 2027, (USD Million)

Table 9 North America Performance Enhancing Drugs by End Users, 2020 – 2027, (USD Million)

Table 10 US Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 11 US Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 12 US Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

Table 13 Canada Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 14 Canada Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 15 Canada Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

Table 16 South America Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 17 South America Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 18 South America Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

Table19 Europe Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 20 Europe Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 21 Europe Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

Table 22 Western Europe Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 23 Western Europe Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 24 Western Europe Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

Table 25 Eastern Europe Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 26 Eastern Europe Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 27 Eastern Europe Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

Table 28 Asia Pacific Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 29 Asia Pacific Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 30 Asia Pacific Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

Table 31 Middle East & Africa Performance Enhancing Drugs Market by Types, 2020 – 2027, (USD Million)

Table 32 Middle East & Africa Performance Enhancing Drugs Market by Products, 2020 – 2027, (USD Million)

Table 33 Middle East & Africa Performance Enhancing Drugs Market by End Users, 2020 – 2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Performance Enhancing Drugs Market

Figure 3 Segmentation Market Dynamics for Global Performance Enhancing Drugs Market

Figure 4 Global Performance Enhancing Drugs Market Share, by Type 2020

Figure 5 Global Performance Enhancing Drugs Market Share, by Products 2020

Figure 6 Global Performance Enhancing Drugs Market Share, by End Users, 2020

Figure 7 Global Performance Enhancing Drugs Market Share, by Region, 2020

Figure 8 North America Performance Enhancing Drugs Market Share, by Country, 2020

Figure 9 Europe Performance Enhancing Drugs Market Share, by Country, 2020

Figure 10 Asia Pacific Performance Enhancing Drugs Market Share, by Country, 2020

Figure 11 Middle East & Africa Rickets Market Share, by Country, 2020

Figure 12 Global Performance Enhancing Drugs Market: Company Share Analysis, 2020 (%)

Figure 13 Taj Pharmaceuticals Limited. : Key Financials

Figure 14 Taj Pharmaceuticals Limited. : Segmental Revenue

Figure 15 Taj Pharmaceuticals Limited. : Geographical Revenue

Figure 16 Balkan Pharmaceuticals. : Key Financials

Figure 17 Balkan Pharmaceuticals. : Segmental Revenue

Figure 18 Balkan Pharmaceuticals. : Geographical Revenue

Figure 19 Bayer AG. : Key Financials

Figure 20 Bayer AG. : Segmental Revenue

Figure 21 Bayer AG. : Geographical Revenue

Figure 22 AstraZeneca: Key Financials

Figure 23 AstraZeneca: Segmental Revenue

Figure 24 AstraZeneca: Geographical Revenue

Figure 25 Novo Nordisk A/S: Key Financials

Figure 26 Novo Nordisk A/S: Segmental Revenue

Figure 27 Novo Nordisk A/S: Geographical Revenue

Figure 28 BrainAlert, LLC: Key Financials

Figure 29 BrainAlert, LLC: Segmental Revenue

Figure 30 BrainAlert, LLC: Geographical Revenue

Figure 31 Douglas Laboratories.: Key Financials

Figure 32 Douglas Laboratories.: Segmental Revenue

Figure 33 Douglas Laboratories.: Geographical Revenue

Figure 34 Onnit Labs, LLC. : Key Financials

Figure 35 Onnit Labs, LLC.: Segmental Revenue

Figure 36 Onnit Labs, LLC. : Geographical Revenue

Figure 37 Eli Lilly and Company. : Key Financials

Figure 38 Eli Lilly and Company. : Segmental Revenue

Figure 39 Eli Lilly and Company. : Geographical Revenue